Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia

14 Dec 2022

Abstract excerpt

Blinatumomab is an efficacious immunotherapeutic agent in B cell acute lymphoblastic leukemia (B-ALL). However, the pharmacogenomic basis of leukemia response to blinatumomab is unclear. Using genome-wide CRISPR, we comprehensively identified leukemia intrinsic factors of blinatumomab sensitivity, i.e., the loss of CD58 as a top driver for resistance, in addition to CD19 . Screening 1639 transcription factor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36516256
DOI: 10.1126/sciadv.add6403

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemiaPMID 36516256Read ↗

PAX5 alterations in B-cell acute lymphoblastic leukemiaSemantic proximity Read ↗

Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALLSemantic proximity Read ↗

Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 casesSemantic proximity Read ↗

Identification of Molecular Subtypes of B-Cell Acute Lymphoblastic Leukemia in Mexican Children by Whole-Transcriptome Analysis.Semantic proximity Read ↗

IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.Semantic proximity Read ↗

Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia.Semantic proximity Read ↗

Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemiaSemantic proximity Read ↗

Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicinSemantic proximity Read ↗

Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL.Semantic proximity Read ↗

14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T and myeloid immature acute leukemiaSemantic proximity Read ↗

The bone marrow microenvironment of RAS pathway mutant B-ALL is enriched for immunosuppressive regulatory T cellsSemantic proximity Read ↗

Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.